Author:
Paschold Lisa,Klee Bianca,Gottschick Cornelia,Willscher Edith,Diexer Sophie,Schultheiß Christoph,Simnica Donjete,Sedding Daniel,Girndt Matthias,Gekle Michael,Mikolajczyk Rafael,Binder Mascha
Abstract
AbstractHigh antibody affinity against the ancestral SARS-CoV-2 strain seems to be necessary (but not always sufficient) for the control of emerging immune-escape variants. Therefore, aiming at strong B cell somatic hypermutation - not only at high antibody titers - is a priority when utilizing vaccines that are not targeted at individual variants. Here, we developed a next-generation sequencing based SARS-CoV-2 B cell tracking protocol to rapidly determine the level of immunoglobulin somatic hypermutation at distinct points during the immunization period. The percentage of somatically hypermutated B cells in the SARS-CoV-2 specific repertoire was low after the primary vaccination series, evolved further over months and increased steeply after boosting. The third vaccination mobilized not only naïve, but also antigen-experienced B cell clones into further rapid somatic hypermutation trajectories indicating increased affinity. Together, the strongly mutated post-booster repertoires and antibodies deriving from this may explain why the booster, but not the primary vaccination series, offers some protection against immune-escape variants such as Omicron B.1.1.529.Brief summaryPriming SARS-CoV-2 vaccinations generate antibodies from low-level matured B cells while the third vaccination strongly boosts somatic hypermutation potentially explaining different protection from immune-escape variants.
Publisher
Cold Spring Harbor Laboratory
Reference57 articles.
1. Robbiani DF , Gaebler C , Muecksch F , Lorenzi JCC , Wang Z , Cho A , et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020.
2. Schafer A , Muecksch F , Lorenzi JCC , Leist SR , Cipolla M , Bournazos S , et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med. 2021;218(3).
3. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2;Sci Immunol,2021
4. The germinal centre B cell response to SARS-CoV-2
5. Schultheiss C , Paschold L , Simnica D , Mohme M , Willscher E , von Wenserski L , et al. Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. Immunity. 2020.